Dyadic International, a Jupiter, Florida-based biopharmaceutical company, has entered into a proof-of-concept research collaboration with an unnamed biotechnology company to use its proprietary C1 gene-expression platform technology to produce an active pharmaceutical ingredient.  

Dyadic’s gene-expression platform is based on the fungus Myceliophthora thermophila, or C1. Dyadic is using the C1 technology and other technologies to conduct research, development, and commercial activities for developing and manufacturing human and animal vaccines, monoclonal antibodies, biosimilars and/or biobetters, and other therapeutic proteins.

Source: Dyadic International